INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD)
© 2026 IJNRD | Volume 11, Issue 2, February 2026 | ISSN: 2456-4184 | IJNRD.ORG

CRISPER-Cas Technology:A Comprehensive Literature review

[1]Nandini Deeliprao Patil,

[1]PhD Student ,
[1] Department of Microbiology ,
[1]Swami Ramanand Teerth Marathwada University Nanded , Maharashtra , India

Abstract : CRISPR–Cas (Clustered Regularly Interspaced Short Palindromic Repeats–CRISPR associated proteins) technology has revolutionized genome engineering by providing a precise, efficient, and cost-effective tool for targeted genetic modification. Originally identified as an adaptive immune system in bacteria and archaea, CRISPR–Cas systems have been repurposed for genome editing in diverse organisms. This review summarizes the historical development, classification, molecular mechanisms, major technological advancements, biomedical and agricultural applications, limitations, and future perspectives of CRISPR–Cas systems. The technology's transformative potential in medicine, functional genomics, and biotechnology is discussed alongside ethical and regulatory considerations.

Keywords: CRISPR, Cas9, genome editing, gene therapy, base editing, prime editing, biotechnology, cultural production; livestock; industrial applications.

INTRODUCTION

Genome editing technologies have evolved from zinc-finger nucleases (ZFNs) and TALENs to the highly versatile CRISPR–Cas systems. CRISPR sequences were first discovered in bacteria in 1987, but their biological function as an adaptive immune system was elucidated in the early 2000s. The universly accepted CRISPER acronym, Clustered Regularly Interspaced Palindromic Repeats was given by Spanish microbiologist Mojika. The CRISPR–Cas system functions as an adaptive immune mechanism in prokaryotes, protecting bacteria from phage infections by incorporating fragments of viral DNA into their own genome as a form of molecular memory. These viral DNA fragments are interspersed between short, repetitive nucleotide sequences known as direct repeats. Adjacent to these repeat–spacer arrays are genes that encode CRISPR-associated (Cas) proteins. Scientists have harnessed this natural system to direct programmable endonucleases to specific genetic targets. As a powerful genome-editing technology, CRISPR enables precise, sequence-specific modifications of DNA or RNA and can be readily reprogrammed for different targets. Cas endonucleases are widely utilized for accurate gene editing and have found extensive applications in agriculture, medicine and infectious disease control, the food industry, and bioenergy production. In 2012–2013, CRISPR–Cas9 was successfully adapted for programmable genome editing in eukaryotic cells, marking a major breakthrough in molecular biology.

Compared to earlier gene-editing tools, CRISPR technology is simpler to design, more efficient, and highly adaptable, leading to widespread adoption across research and therapeutic fields.

Phase	Time Period	Key Discoveries / Events Significance	Important Scientists / Findings	Significance
Identification phase	1987–1993	First observation of unusual direct repeats (24 nt) in E. coli during alkaline phosphatase gene study (1987). Similar repeats found in Haloferax mediterranei (30–34 nt repeats with 35 bp spacers	Early researchers studying repetitive DNA sequences	Discovery of repeat–spacer structure; spacers between repeats intrigued scientists.
Structural & Functional Characterization Phase	1993—2011	Repeated sequences found widely in bacteria and archaea. Term "CRISPR" coined in 2002. Cas genes identified near CRISPR loci. Spacers	Ruud Jansen (2002) – named CRISPR; Eugene V. Koonin (2006) – proposed RNA interference-like immune role; Kira S.	Established CRISPR–Cas as an adaptive immune system in prokaryotes. Demonstrated viral resistance via spacer

		linked to bacteriophages (2005). Functional link between CRISPR and Cas proposed.	Makarova (2011) – evolutionary analysis	acquisition from phages.
Application Phase	2011–Present	CRISPR repurposed as genome-editing tool. CRISPR–Cas9 transferred between species. Cas9 engineered as transcriptional regulator. Expanded CRISPR toolbox.	David Bikard – engineered Cas9 as transcriptional repressor; multiple global research groups	Development of precise gene-editing technology. Applications in medicine, agriculture, animal husbandry, synthetic biology, biotechnology, and disease research.

2. Classification of CRISPR–Cas Systems

CRISPR systems are broadly classified into two classes:
Class 1 Systems:-
Utilize multi-protein effector complexes
Include Types I, III, and IV
More common in nature
Class 2 Systems:-
Use a single effector protein
Include Types II (Cas9), V (Cas12), and VI (Cas13)
Widely used in genome engineering Among these, Cas9 (Type II) is the most extensively studied and applied nuclease**.**

3. Mechanism of CRISPR–Cas9 Genome Editing

The CRISPR–Cas9 system operates in three stages:
3.1 Adaptation :-
Foreign DNA fragments (spacers) from invading viruses are incorporated into the CRISPR locus.
3.2 Expression:-
The CRISPR array is transcribed into pre-crRNA, which is processed into mature crRNA. In engineered systems, a single guide RNA (sgRNA) combines crRNA and tracrRNA functions.
3.3 Interference:-
The Cas9–sgRNA complex binds to a complementary DNA sequence adjacent to a PAM (Protospacer Adjacent Motif) and introduces a double-strand break (DSB).
The DSB is repaired by:
Non-Homologous End Joining (NHEJ) – introduces insertions/deletions
Homology-Directed Repair (HDR) – enables precise gene correction
The methodology section outline the plan and method that how the study is conducted. This includes Universe of the study, sample of the study,Data and Sources of Data, study's variables and analytical framework. The detailsare as follows;

Stage	Also Known As	Process Description	Key Proteins / Components	Important Features
1.Adaptation	Spacer acquisition / Insertion	Foreign DNA fragments (from phage/plasmid) are incorporated into the CRISPR array as new spacers at the leader end. Type I system: IHF binds leader → DNA bending → Cas1–Cas2 complex inserts spacer. Type II system: Leader Anchoring Sequence (LAS) recognized by Cas1 → polar spacer insertion.	$(Cas1–Cas2)_2$ heterohexameric complex Integration Host Factor (IHF), Cas1, Cas2 Cas1 protein, LAS	Adds new spacer into CRISPR locus, creating immune memory. DNA bending required for spacer insertion. Does not require IHF-mediated bending.
Expression	crRNA biogenesis / crRNA processing Cas processing enzymes (vary by type/subtype)	CRISPR array is transcribed into long precursor crRNA (pre-crRNA), then processed into mature crRNAs	Cas processing enzymes (vary by type/subtype)	Pre-crRNA cleaved within repeat sequences; may undergo 5′ or 3′ trimming.
Interference	Target cleavage stage	crRNA guides Cas proteins to recognize and cleave invading viral/plasmid DNA. Some systems require PAM recognition before cleavage	Class 1: Multi-protein complex + crRNA; Class 2: Single Cas protein (e.g., Cas9) + crRNA PAM (Protospacer Adjacent Motif)	Recognition of complementary target sequence. Cleavage inactivates invading genome. PAM is absent in host genome → ensures self vs non-self discrimination.



4. Advancements in CRISPR Technologies

To overcome limitations of double-strand breaks, several modified systems have been developed:

4.1 Base Editing:-

Many genetic diseases happen because of a single base mutation in DNA. The ideal treatment is to correct the wrong base directly, not to cut the DNA and depend on random repair (like HDR or NHEJ), which older CRISPR tools mainly do.

Cytosine Base Editing (CBE)

Scientists discovered that enzymes such as cytidine deaminase can change cytosine (C) into uracil (U), which is later converted to thymine (T). This results in a C-G to T-A base change. These tools are called cytosine base editors (CBEs)

Adenine Base Editing (ABE)

Some diseases require changing A-T to G-C. However, no natural enzyme edits adenine in double-stranded DNA. Researchers modified a bacterial enzyme (TadA) to create adenine base editors.

Limitations of CBE and ABE

Although CBEs and ABEs can efficiently substitute certain bases, they cannot freely perform all types of insertions, deletions, or substitutions.



4.2 Prime Editing:-

To solve the problem in Base Editing scientists developed prime editing. It combines:

A modified Cas9 (Cas9 nickase),

A reverse transcriptase (RT) enzyme,

A special guide RNA (pegRNA) that contains instructions for the desired edit.

Prime editing can:

Make almost any base substitution,

Insert new DNA,

Delete DNA sequences.

Improved versions (PE2, PE3, PE3b) increased editing efficiency, but PE3/PE3b may carry some risks because Cas9 cannot perfectly distinguish between guide RNAs.



4.3 CRISPR Interference (CRISPRi) and Activation (CRISPRa):-

CRISPR Interference (CRISPRi)

CRISPR interference (CRISPRi) is a method used to turn OFF a gene without cutting DNA.
It uses a dead Cas9 (dCas9) — a modified version of Cas9 that cannot cut DNA.
dCas9 is guided to a specific gene by a guide RNA (sgRNA).
Once it binds to the DNA, it blocks RNA polymerase, preventing transcription.
The gene is silenced, but the DNA sequence remains unchanged.

CRISPR Activation (CRISPRa)

CRISPR activation (CRISPRa) is used to turn ON or increase expression of a gene, again without cutting DNA.
It also uses dCas9, but this time it is fused to transcriptional activator proteins (like VP64).
When guided to a gene promoter, it recruits transcription machinery.
This increases gene expression.

4.4 RNA Editing:-

CRISPR/Cas13a is a bacterial immune system that protects against RNA viruses. Unlike Cas9, which cuts DNA, Cas13a specifically recognizes and cuts RNA using a special HEPN nuclease domain. After cutting its target RNA, it continues cutting other nearby RNAs — this is called collateral cleavage.
RNA is very important in cells, so scientists developed ways to reduce (knockdown) specific RNAs to study gene function. RNA interference (RNAi) is one such method and works well, but it often affects unintended targets. CRISPR/Cas13a can also knock down RNA, similar to RNAi, but with fewer off-target effects.
A modified inactive version called dCas13a can be attached to other molecules to control RNA functions without cutting it. It can regulate RNA methylation (like m6A), change RNA bases, and control protein translation.
Cas13a is also used for detecting RNA. In 2017, Feng Zhang and his team developed a detection method called Specific High Sensitivity Enzymatic Reporter UnLOCKing (SHERLOCK). It produces a fluorescent signal when target RNA is present. Later, the sensitivity was improved using RNA amplification techniques. This improved method was successfully applied in 2020 for detecting SARS-CoV-2.



5. Applications of CRISPR–Cas Technology

1. In Plant Biotechnology (Agriculture)

A. Increasing Crop Yield and Quality
Mechanism:
CRISPR uses Cas9 or Cas12a protein + guide RNA (sgRNA). The guide RNA binds to a specific DNA sequence near a PAM site. Cas protein cuts DNA (double-strand break). The plant repairs the break by:
NHEJ (error-prone repair) → small insertions/deletions → gene knockout.
HDR (precise repair) → gene insertion or replacement.
Applications:
Increase grain size, weight, number.Increase amylose and protein content.Delay fruit ripening.Improve shelf life.Reduce gluten.Increase healthy fats (oleic acid). Produce seedless fruits.

B. Stress Resistance
Mechanism:
Stress-related genes are either: Knocked out (if they suppress resistance), or
Activated/modified (if they improve tolerance). Sometimes multiple genes are edited at once (multiplex editing). Cas12a is useful because it can create larger deletions and edit multiple genes.
Result:
Plants become resistant to:
Abiotic stress:Drought, Heat, Cold, Salt
Biotic stress:Virus, Bacteria, Fungi, Insects

C. Herbicide Resistance
Mechanism:
CRISPR edits target genes like ALS or EPSPS. Either mutation or base editing changes one nucleotide. The new enzyme becomes insensitive to herbicide.
Result: Plant survives herbicide spray.

D. Hybrid Seed Production
Mechanism:
Male fertility genes (like TMS5, Ms45) are knocked out. This creates male-sterile plants. These are used for high-yield hybrid seed production.

E. RNA Virus Targeting (Cas13a)
Mechanism:
Cas13a binds to RNA instead of DNA. It does NOT need PAM.
crRNA binds complementary viral RNA. HEPN domains cut the target RNA.
Result:
Viral RNA destroyed. Reduced viral load. Can detect single RNA molecules.

2. In Human Therapeutics

Treatment of Genetic Diseases
General Mechanism:
Cas9 + sgRNA delivered using viral vectors (like AAV). Cas9 cuts mutated DNA.
Repair occurs by:
NHEJ → gene disruption.
HDR → precise gene correction.

1. Duchenne Muscular Dystrophy (DMD)
Mechanism:
Mutation in dystrophin gene. CRISPR removes faulty exon (like exon 44 or 50). Restores reading frame. Dystrophin protein production resumes.

2.Sickle Cell Disease / Beta-Thalassemia
Mechanism:
Target BCL11A enhancer. Deleting 200 bp region increases fetal hemoglobin. Fetal hemoglobin compensates defective adult hemoglobin.

2. Alpha-1 Antitrypsin Deficiency
Mechanism:
Mutant SERPINA1 gene disrupted. Reduces toxic protein accumulation in liver.

3. Hearing Loss (Tmc1 mutation)
Mechanism:
Cas9 disrupts mutant Tmc1 gene. Delivered via AAV. Prevents progressive deafness.

B. Infectious Diseases

- HIV

Mechanisms Used:
Targeting Viral DNA Cas9 cuts HIV LTR regions. Removes proviral DNA from host genome. Blocking Entry Edit CCR5 or CXCR4 receptors. Without these receptors, HIV cannot enter T cells. Cas12a Action High specificity cleavage. Efficient HIV genome inactivation.

- SARS-CoV-2 Detection

Mechanism (AIOD-CRISPR, Cas12a):
Viral RNA amplified. Cas12a recognizes target. Once activated, Cas12a cuts reporter molecules. Fluorescence signal produced.
Result: Rapid and sensitive detection.

- HSV, EBV, HCMV

Mechanism:
sgRNA targets viral replication genes (ICP0, ICP4, UL122/123). Cas9 cuts viral genome. Reduces viral protein production. Prevents replication and reactivation.

C. Cancer Applications
1.Knockout of Oncogenes
Mechanism:
Cas9 disrupts proto-oncogenes (e.g., CD38). Tumor growth reduces.

2.Tumor Suppressor Study
Mechanism:
Knockout tumor suppressor genes in models. Understand how cancer develops.

3.Cancer Immunotherapy (CAR-T)
Mechanism:
CRISPR edits T cells. Inserts CAR gene into TRAC locus. Knocks out PD-1 checkpoint gene. Engineered T cells better kill cancer cells.

4. SHERLOCK (Cancer Detection)

Mechanism:
Cas13a binds cancer RNA markers. Activated Cas13a cuts reporter RNA. Fluorescence indicates presence of cancer biomarker.

3. Food Industry & Microbial Engineering

Mechanism:
Knockout metabolic pathway genes. Insert biosynthetic gene clusters. Use CRISPRi (gene repression without cutting DNA). Use multiplex editing for pathway optimization.
Applications:
Increased biofuel production.
Increased organic acids (citric acid, succinate).
Increased amino acids (GABA).
Increased fatty acids.
Removal of mycotoxins.
Improved fermentation strains.

6. Limitations and Challenges

1. Off-target effects (Editing the wrong DNA)
CRISPR sometimes cuts DNA at the wrong place. This happens when the guide RNA (sgRNA) partly matches other DNA sequences. Even small mismatches can still allow cutting. These unwanted changes can create unknown mutations, which may be harmful. Scientists have developed improved Cas9 versions (like high-fidelity variants) and modified sgRNAs to reduce this problem, but it is still a major challenge.

2. Chromosomal damage
CRISPR cuts both strands of DNA. While cells repair these cuts, mistakes can occur. Sometimes large DNA pieces are deleted or chromosomes rearrange (translocations). These changes can cause serious problems like cancer. Repeated cutting increases this risk.

4. Risk of cancer (TP53 problem)

CRISPR cutting can activate a gene called TP53, which may cause cells to die. If TP53 is turned off to prevent cell death, it may increase the chance of cancer and more off-target mutations. Some studies linked CRISPR editing with increased cancer risk.

5. Immune system reaction

The Cas9 protein comes from bacteria (such as Streptococcus pyogenes and Staphylococcus aureus). The human immune system may recognize it as foreign and attack it. This can reduce effectiveness and cause side effects. Scientists are trying to modify Cas9 to reduce immune responses.

6. PAM sequence restriction

Cas9 can only cut DNA near specific short sequences called PAM sites. If the correct PAM is not present, editing cannot occur at that location. New variants like SpRY and modified Nme2Cas9 reduce this restriction, but some may increase off-target effects.

7. Limited gene activation efficiency

When CRISPR is used to turn genes on or off (CRISPRa/CRISPRi), the effect may not be strong enough for treatment. Efficiency depends on sgRNA position, cell type, and activation domains. Multiple sgRNAs or stronger activation systems are sometimes required.

8. Delivery challenges

Getting CRISPR safely into the correct cells is difficult. Scientists use viruses, nanoparticles, plasmids, or ribonucleoproteins, but:
It may enter healthy (non-target) cells.
The body may destroy the delivery system.
It may cause immune reactions. Targeted and biocompatible delivery systems are still being improved.

9. Ethical concerns (especially in humans)

Editing human embryos or germline cells raises serious ethical and legal concerns. Changes can be passed to future generations. Many countries restrict or ban human germline editing. There are fears about inequality, misuse, and "designer babies."

10. Gene drive risks

CRISPR gene drive spreads genetic changes quickly through populations (like mosquitoes). This could eliminate disease-carrying species but may cause ecological imbalance or even species extinction. No gene drive organism has yet been released into the wild.

11. Biosecurity risks

CRISPR could be misused to create harmful bacteria, viruses, or biological weapons. Because CRISPR is affordable and easy to use, there is concern about accidental or intentional misuse.

7. Ethical Considerations

1. Technical Limitations and Scientific Uncertainty

Although CRISPR is powerful, it is not perfect. Major concerns include:
Limited on-target efficiency – Editing may not occur in all intended cells.
Mosaicism – Some cells are edited, others are not.
Off-target effects – Unintended DNA regions may be altered.
Incomplete editing – Desired correction may not fully restore function.
Even though technology is rapidly improving (e.g., base editing, prime editing), uncertainty remains. Ethical concern arises because:
If we cannot fully control or predict the outcome, how can we justify clinical application—especially in humans?
Risk–benefit analysis becomes difficult when outcomes are probabilistic rather than predictable.

2.Heritability and Long-Term Consequences

Editing can occur in:
Somatic cells → affects only the treated individual
Germline cells (embryos, sperm, eggs) → changes are inherited by future generations
Germline editing raises deeper ethical issues because:
Effects may be permanent and transgenerational.
Future individuals cannot consent.
Unintended consequences may only appear decades later.
Because biology is complex and nonlinear, predicting long-term outcomes is extremely difficult.

2. Complexity of Genotype–Phenotype Relationships

A major scientific limitation with ethical implications is that:
Most traits are polygenic and context-dependent.
One gene rarely determines a complex trait.
Regulatory elements (enhancers, repressors), epigenetics, and environment all influence phenotype.
Editing one gene may produce unexpected downstream effects.
Thus, even a technically "successful" edit does not guarantee a predictable biological outcome.
This scientific uncertainty directly complicates ethical decision-making. If we do not fully understand gene networks, how can we confidently assess risks?

3. Regulatory Oversight and Governance

Regulatory systems aim to reduce risk. In the United States, CRISPR-based therapies are regulated by:
U.S. Food and Drug Administration (FDA)
Center for Biologics Evaluation and Research (CBER)
Office of Cellular, Tissue, and Gene Therapies (OCTGT)

These agencies classify many CRISPR therapies as biological products, subject to strict safety and efficacy evaluation. However, ethical concerns increase in regions where:
Regulatory infrastructure is weak
Oversight is insufficient
Data privacy protections are limited
The global nature of science means uneven regulation can create "ethics gaps."
Simultaneously, tension is unavoidable.

Key Ethical Themes Summarized

Scientific Issue	Ethical Challenge
Off-target edits	Risk of unintended harm
Mosaicism	Incomplete therapeutic benefit
Germline editing	Intergenerational impact
Polygenic traits	Unpredictable phenotype outcomes
Weak regulation	Safety and equity concerns

8. Future Perspectives

1. Development of High-Fidelity Cas Variants

One of the main limitations of early CRISPR–Cas9 systems was off-target activity, where unintended DNA sequences were edited. To overcome this: High-fidelity Cas variants (e.g., enhanced specificity Cas9, SpCas9-HF1, eSpCas9) have been engineered. These variants reduce non-specific DNA interactions. They improve safety for clinical applications.
Significance:
Reducing off-target mutations is essential for therapeutic genome editing, especially in human gene therapy where unintended edits could cause harmful mutations.

2. AI-Assisted Guide RNA (gRNA) Design

The efficiency and specificity of CRISPR depend heavily on guide RNA design. Artificial Intelligence and machine learning models are now used to:
Predict on-target efficiency.
Minimize off-target binding.
Optimize GC content and secondary structures.
Analyze genome-wide datasets for better targeting.
AI tools integrate large genomic datasets to design highly precise gRNAs, increasing editing success rates.
Future Impact:
AI-guided design enhances precision medicine approaches by tailoring edits to individual genetic profiles.

3. In Vivo Genome Editing Therapies

Traditional gene editing often required ex vivo modification (editing cells outside the body and reinfusing them). Emerging approaches now focus on:
Direct in vivo delivery using viral vectors (e.g., AAV).
Lipid nanoparticles for CRISPR component delivery.
Tissue-specific targeting systems.
In vivo editing allows treatment of genetic diseases directly within organs such as liver, muscle, or blood cells.
Clinical Relevance:
This approach holds promise for treating inherited disorders, hematologic diseases, and certain cancers with permanent correction of mutations.

4. Expansion of CRISPR-Based Diagnostics

CRISPR systems are now being used beyond editing for rapid disease detection. Two major platforms include:
SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing)
DETECTR (DNA Endonuclease Targeted CRISPR Trans Reporter)
These systems utilize collateral cleavage activity of Cas proteins (e.g., Cas12, Cas13) to detect:
Viral RNA/DNA
Bacterial infections
Cancer biomarkers
Advantages:
Rapid detection
High sensitivity and specificity
Minimal laboratory equipment
Potential for point-of-care diagnostics

5. Exploration of Novel Cas Proteins

Beyond Cas9, researchers are discovering and characterizing new Cas enzymes such as:
Cas12 (DNA targeting with collateral cleavage)
Cas13 (RNA targeting)
Cas14 (ultra-small DNA targeting systems)
These novel proteins expand the CRISPR toolbox by:
Targeting RNA instead of DNA
Allowing multiplex editing
Offering smaller proteins for easier delivery
Enabling base editing and prime editing strategies
Importance:
Diversifying Cas proteins enhances flexibility, reduces delivery challenges, and improves specificity.

6. Applications in Personalized Medicine

CRISPR enables:
Patient-specific mutation correction.
Cancer immunotherapy (e.g., engineered T cells).
Pharmacogenomic optimization.
Tailored treatment strategies based on individual genomes.
It supports precision medicine by moving from generalized therapy to individualized genetic correction.

7. Applications in Precision Agriculture

In agriculture, CRISPR supports:
Climate-resilient crops.
Disease-resistant plants.
Improved yield and nutritional content.
Reduced pesticide dependency.
Unlike traditional GMOs, CRISPR can introduce precise edits without foreign DNA integration, potentially simplifying regulatory pathways.

9.Conclusion

The CRISPR–Cas system represents a transformative advancement in genetic engineering. It has moved beyond simple DNA cleavage to include single-base editing, transcriptional regulation, and RNA targeting, greatly expanding its therapeutic and biotechnological applications.
CRISPR has already demonstrated significant potential in:
Agriculture – improving crop yield, nutritional quality, and resistance to viruses, herbicides, drought, salinity, and cold stress, paving the way for next-generation crop varieties.
Industrial biotechnology – enhancing biofuel production and development of new biomaterials.
Medicine – offering promising treatments for cancer, chronic diseases, and monogenic genetic disorders.
However, despite its powerful gene-editing capability (especially with systems like CRISPR–Cas9), several major challenges remain before full clinical application:

Safe and Efficient Delivery Current delivery forms (plasmid DNA, mRNA, RNP) are rapidly cleared by the immune system.
Viral vectors such as Adeno-associated virus (AAV) are widely used but pose risks like genome integration and limited cargo capacity.
Nonviral vectors such as lipid nanoparticles (LNPs) and gold nanoparticles (AuNPs) offer alternatives but may still trigger immune responses or accumulate in non-target organs.
Emerging strategies using exosomes, biofilm coatings, and disease-targeting peptides show promise for improving specificity and avoiding immune clearance.
Targeted Delivery Based on Disease Microenvironment
Diseased tissues exhibit altered microenvironments and overexpress specific membrane proteins. Designing nanomaterials that respond to disease-specific conditions or recognize overexpressed proteins may enhance precise delivery to affected cells.
Safety and Off-Target Effects
Off-target editing remains a critical concern.
Engineering high-fidelity Cas9 variants and optimizing sgRNA design significantly reduce unintended edits.
Continued refinement of enzyme specificity is essential for clinical safety.
Ethical Considerations
While CRISPR holds the potential to improve quality of life, revive extinct species, and even create novel organisms, misuse poses serious ethical and societal risks.
Ongoing ethical discussion and regulation are necessary to ensure responsible application.

CRISPR–Cas technology marks the beginning of a new era in genome engineering. Although challenges related to delivery, safety, and ethics remain, ongoing advancements in vector development, enzyme specificity, and disease-targeted strategies are steadily moving CRISPR toward full clinical and industrial implementation. With responsible use and continued innovation, CRISPR holds immense promise for improving human health, agriculture, and sustainable development.

10. References

1. Marraffini, L. A. & Sontheimer, E. J. Self versus non-self discrimination duringMCRISPR RNA-directed immunity. Nature 463, 568–571 (2010).
2. Manghwar, H., Lindsey, K., Zhang, X. & Jin, S. CRISPR/Cas system: recent advances And future prospects for genome editing. Trends Plant Sci. 24, 1102–1125 (2019).
3. Roth, T. L. & Marson, A. Genetic disease and therapy. Annu. Rev. Pathol. 16,145–166 (2021).
4. Gaj, T., Gersbach, C. A. & Barbas, C. F. 3rd ZFN, TALEN, and CRISPR/Cas-based Methods for genome engineering. Trends Biotechnol. 31, 397–405 (2013).
5. Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPRCas9 fgenome engineering. Cell 157, 1262–1278 (2014).
6. Cox, D. B., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and Challenges. Nat. Med. 21, 121–131 (2015).
7. Pickar-Oliver, A. & Gersbach, C. A. The next generation of CRISPR-Cas technologies and applications. Nat. Rev. Mol. Cell Biol. 20, 490–507 (2019).
8. Mojica, F. J., Díez-Villaseñor, C., García-Martínez, J. & Soria, E. Intervening Sequences of regularly spaced prokaryotic repeats derive from foreign genetic Elements. J. Mol. Evol. 60, 174–182 (2005).Marraffini, L. A. & Sontheimer, E. J. Self versus non-self discrimination during CRISPR RNA-directed immunity. Nature 463, 568–571 (2010).
10. Li, J. et al. Genome editing mediated by SpCas9 variants with broad noncanonical PAM compatibility in plants. Mol. Plant. 14, 352–360 (2021).
11. Bolotin, A., Quinquis, B., Sorokin, A. & Ehrlich, S. D. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal Origin. Microbiology 151, 2551–2561 (2005).
12. Chen, K. Et al. CRISPR/Cas genome editing and precision plant breeding in Agriculture. Annu. Rev. Plant Biol. 70, 667–697 (2019).
13. Platt, R. J. Et al. CRISPR-Cas9 knockin mice for genome editing and cancer Modeling. Cell 159, 440–455 (2014).
14. Jiang, F. & Doudna, J. A. CRISPR-Cas9 structures and mechanisms. Annu. Rev. Biophys. 46, 505–529 (2017).
15. Doudna, J. A. & Charpentier, E. Genome editing. The new frontier of genome Engineering with CRISPR-Cas9. Science 346, 1258096 (2014).

16. Zhan, T. Et al. CRISPR/Cas9 for cancer research and therapy. Semin. Cancer Biol. 55, 106–119 (2019).
17. Vermersch, E., Jouve, C. & Hulot, J. S. CRISPR/Cas9 gene-editing strategies in Cardiovascular cells. Cardiovasc. Res. 116, 894–907 (2020).
18. Newby, G. A. Et al. Base editing of haematopoietic stem cells rescues sickle cell Disease in mice. Nature 595, 295–302 (2021).
19. Heidenreich, M. & Zhang, F. Applications of CRISPR-Cas systems in neuroscience. Nat. Rev. Neurosci. 17, 36–44 (2016).
20. Wu, Y. Et al. Correction of a genetic disease by CRISPR-Cas9-mediated gene Editing in mouse spermatogonial stem cells. Cell Res. 25, 67–79 (2015).
21. Fu, Y. W. Et al. Dynamics and competition of CRISPR-Cas9 ribonucleoproteins And AAV donor-mediated NHEJ, MMEJ and HDR editing. Nucleic Acids Res. 49, 969–985 (2021).
22. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).
23. Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44, D862–868 (2016).
24. Qi, L. S. et al. Repurposing CRISPR as an RNA-guided
25. Komor, A. C. et al. Programmable editing of a target base in genomic DNA Without double-stranded DNA cleavage. Nature 533, 420–424 (2016).
26. Gaudelli, N. M. et al. Programmable base editing of A•T to G•C in genomic DNA Without DNA cleavage. Nature 551, 464–471 (2017).
27. Anzalone, A. V. et al. Search-and-replace genome editing without double-strand Breaks or donor DNA. Nature 576, 149–157 (2019).
28. Abudayyeh, O. O. et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science 353, aaf5573 (2016).
29. Behr, M., Zhou, J., Xu, B. & Zhang, H. In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges. Acta Pharm. Sin. B. 11, 2150–2171 (2021).
30. Wang, D., Zhang, F. & Gao, G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 181, 136–150 (2020).
31. Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493–502 (2021).
32. Chen, F., Alphonse, M. & Liu, Q. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 12, e1609 (2020).
33. Cai, W., Luo, T., Mao, L. & Wang, M. Spatiotemporal delivery of CRISPR/Cas9 genome editing machinery using stimuli-responsive vehicles. Angew. Chem. Int.
Ed. Engl. 60, 8596–8606 (2021).
34. Jiang, W.Z.; Henry, I.M.; Lynagh, P.G.; Comai, L.; Cahoon, E.B.; Weeks, D.P. Significant enhancement of fatty acid composition in seeds of the allohexaploid, cCamelina sativa, using CRISPR/Cas9 gene editing. Plant Biotechnol. J. 2017, 15, 648–657.
35. Sánchez-León, S.; Gil-Humanes, J.; Ozuna, C.V.; Giménez, M.J.; Sousa, C.; Voytas, D.F.; Barro, F. Low-gluten, nontransgenic wheatengineered with CRISPR/Cas9. Plant Biotechnol. J. 2018, 16, 902–910.
36. Aznar-Moreno, J.A.; Durrett, T.P. Simultaneous targeting of multiple gene homeologs to alter seed oil production in Camelina sativa. Plant Cell Physiol. 2017, 58, 1260–1267.
37. Sun, Y.; Jiao, G.; Liu, Z.; Zhang, X.; Li, J.; Guo, X.; Du, W.; Du, J.; Francis, F.; Zhao, Y.; et al. Generation of high-amylose rice through CRISPR/Cas9-mediated targeted mutagenesis of starch branching enzymes. Front. Plant Sci. 2017, 8.
38. Shan, Q.; Wang, Y.; Li, J.; Zhang, Y.; Chen, K.; Liang, Z.; Zhang, K.; Liu, J.; Xi, J.J.; Qiu, J.-L.; et al. Targeted genome modification of crop plants using a CRISPR-cas system. Nat. Biotechnol. 2013, 31, 686–688.
39. Klap, C.; Yeshayahou, E.; Bolger, A.M.; Arazi, T.; Gupta, S.K.; Shabtai, S.; Usadel, B.; Salts, Y.; Barg, R. Tomato facultative parthenocarpy results from SlAGAMOUS-LIKE 6 loss of function. Plant Biotechnol. J. 2017, 15, 634–647.
40. Lu, H.-P.; Luo, T.; Fu, H.-W.; Wang, L.; Tan, Y.-Y.; Huang, J.-Z.; Wang, Q.; Ye, G.-Y.; Gatehouse, A.M.R.; Lou, Y.-G.; et al. Resistance of Rice to Insect Pests Mediated by Suppression of Serotonin Biosynthesis. Nat. Plants 2018, 4, 338–344.
41. Christian, M.; Cermak, T.; Doyle, E.L.; Schmidt, C.; Zhang, F.; Hummel, A.; Bogdanove, A.J.; Voytas, D.F. Targeting DNA Double-Strand Breaks with TAL Effector Nucleases. Genetics 2010, 186, 757–761.
42. Chen, K.; Wang, Y.; Zhang, R.; Zhang, H.; Gao, C. CRISPR/Cas genome editing and precision plant breeding in agriculture.Annu. Rev. Plant Biol. 2019, 70, 667–697.
43. Kim, H.; Kim, S.-T.; Ryu, J.; Kang, B.-C.; Kim, J.-S.; Kim, S.-G. CRISPR/Cpf1-mediated DNA-free plant genome editing. Nat. Commun. 2017, 8, 14406.
44. Xu, R.; Li, H.; Qin, R.; Wang, L.; Li, L.; Wei, P.; Yang, J. Gene targeting using the Agrobacterium Ttumefaciens-mediated CRISPR-cas system in rice. Rice 2014, 7, 5.

45. Yin, K.; Han, T.; Liu, G.; Chen, T.; Wang, Y.; Yu, A.Y.L.; Liu, Y. A Geminivirus-based guide RNA delivery system for CRISPR/Cas9 mediated plant genome editing. Sci. Rep. 2015, 5, 14926.
46. Baltes, N.J.; Hummel, A.W.; Konecna, E.; Cegan, R.; Bruns, A.N.; Bisaro, D.M.; Voytas, D.F. Conferring resistance to geminiviruses with the CRISPR-cas prokaryotic immune System. Nat. Plants 2015, 1, 15145.
47. Feng, Z.; Mao, Y.; Xu, N.; Zhang, B.; Wei, P.; Yang, D.-L.; Wang, Z.; Zhang, Z.; Zheng, R.; Yang, L.; et al. Multigeneration analysis reveals the inheritance, specificity, and patterns of CRISPR/cas-induced gene modifications in arabidopsis. Proc. Natl. Acad.Sci. USA 2014, 111, 4632–4637.
48. Puchta, H. Using CRISPR/cas in three dimensions: Towards synthetic plant genomes, transcriptomes and epigenomes. Plant J.2016, 87, 5–15.
49. Aman, R.; Ali, Z.; Butt, H.; Mahas, A.; Aljedaani, F.; Khan, M.Z.; Ding, S.; Mahfouz, M. RNA Virus interference via CRISPR/Cas13a system in plants. Genome Biol. 2018, 19, 1.
50. Abudayyeh, O.O.; Gootenberg, J.S.; Essletzbichler, P.; Han, S.; Joung, J.; Belanto, J.J.; Verdine, V.; Cox, D.B.T.; Kellner, M.J.; Regev, A.; et al. RNA targeting with CRISPR-Cas13. Nature 2017, 550, 280–284.
51. Zhou, H.; He, M.; Li, J.; Chen, L.; Huang, Z.; Zheng, S.; Zhu, L.; Ni, E.; Jiang, D.; Zhao, B.; et al. Development of commercial thermo-sensitive genic male sterile rice accelerates hybrid rice breeding using the CRISPR/Cas9-Mediated TMS5 editing system.
Sci. Rep. 2016, 6, 37395.
52. Svitashev, S.; Schwartz, C.; Lenderts, B.; Young, J.K.; Mark Cigan, A. Genome editing in maize directed by CRISPR–Cas9 ribonucleoprotein complexes. Nat. Commun. 2016, 7, 13274.
53. Singh, M.; Kumar, M.; Albertsen, M.C.; Young, J.K.; Cigan, A.M. Concurrent modifications in the three homeologs of Ms45 gene with CRISPR-Cas9 lead to rapid generation of male sterile bread wheat (Triticum Aaestivum, L.). Plant. Mol. Biol. 2018, 97, 371–383.
54. Yao, L.; Zhang, Y.; Liu, C.; Liu, Y.; Wang, Y.; Liang, D.; Liu, J.; Sahoo, G.; Kelliher, T. OsMATL mutation induces haploid seed formation in indica rice. Nat. Plants 2018, 4, 530–533.
55. Shimatani, Z.; Kashojiya, S.; Takayama, M.; Terada, R.; Arazoe, T.; Ishii, H.; Teramura, H.; Yamamoto, T.; Komatsu, H.;Miura, K.; et al. Targeted base editing in rice and tomato using a CRISPR-Cas9 cytidine deaminase fusion. Nat. Biotechnol. 2017, 35, 441–443.
56. Chen, Y.; Wang, Z.; Ni, H.; Xu, Y.; Chen, Q.; Jiang, L. CRISPR/Cas9-mediated base-editing system efficiently generates gain-offunction mutations in arabidopsis. Sci. China Life Sci. 2017, 60, 520–523.
57. Tian, S.; Jiang, L.; Cui, X.; Zhang, J.; Guo, S.; Li, M.; Zhang, H.; Ren, Y.; Gong, G.; Zong, M.; et al. Engineering herbicide-resistant watermelon variety through CRISPR/Cas9-mediated base-editing. Plant Cell Rep. 2018, 37, 1353–1356.
58. Malnoy, M.; Viola, R.; Jung, M.-H.; Koo, O.-J.; Kim, S.; Kim, J.-S.; Velasco, R.; Nagamangala Kanchiswamy, C. DNA-free genetically edited grapevine and apple protoplast using CRISPR/Cas9 ribonucleoproteins. Front. Plant Sci. 2016, 7, 1904.
59. Ji, L.; Jordan, W.T.; Shi, X.; Hu, L.; He, C.; Schmitz, R.J. TET-mediated epimutagenesis of the Arabidopsis thaliana methylome. Nat. Commun. 2018, 9, 895.
60. Tripathi, L.; Ntui, V.O.; Tripathi, J.N. CRISPR/Cas9-based genome editing of banana for disease resistance. Curr. Opin. Plant Biol. 2020, 56, 118–126.
61. Gomez, M.A.; Lin, Z.D.; Moll, T.; Luebbert, C.; Chauhan, R.D.; Vijayaraghavan, A.; Kelley, R.; Beyene, G.; Taylor, N.J.; Carrington, J.; et al. Simultaneous CRISPR/Cas9-mediated editing of cassava EIF4E isoforms NCBP-1 and NCBP-2 confers elevated resistance to cassava brown streak disease. bioRxiv 2017, 209874.
62. Hummel, A.W.; Chauhan, R.D.; Cermak, T.; Mutka, A.M.; Vijayaraghavan, A.; Boyher, A.; Starker, C.G.; Bart, R.; Voytas, D.F.;Taylor, N.J. Allele exchange at the EPSPS locus confers glyphosate tolerance in cassava. Plant Biotechnol. J. 2018, 16, 1275–1282.
63. Peng, A.; Chen, S.; Lei, T.; Xu, L.; He, Y.; Wu, L.; Yao, L.; Zou, X. Engineering canker-resistant plants through CRISPR/Cas9-targeted editing of the susceptibility gene CsLOB1 promoter in citrus. Plant Biotechnol. J. 2017, 15, 1509–1519.
64. Jia, H.; Zhang, Y.; Orbovi´c, V.; Xu, J.; White, F.F.; Jones, J.B.; Wang, N. Genome editing of the disease susceptibility gene CsLOB1in citrus confers resistance to citrus canker. Plant Biotechnol. J. 2017, 15, 817–823.
65. Fister, A.S.; Landherr, L.; Maximova, S.N.; Guiltinan, M.J. Transient expression of CRISPR/Cas9 machinery targeting TcNPR3 enhances defense response in theobroma cacao. Front. Plant Sci. 2018, 9, 268.
66. Iqbal, Z.; Sattar, M.N.; Shafiq, M. CRISPR/Cas9: A tool to circumscribe cotton leaf curl disease. Front. Plant Sci. 2016, 7.
67. Zhang, Z.; Ge, X.; Luo, X.; Wang, P.; Fan, Q.; Hu, G.; Xiao, J.; Li, F.; Wu, J. Simultaneous editing of two copies of Gh14-3-3d confers enhanced transgene-clean plant defense against Verticillium Dahliae in allotetraploid uplan cotton. Front. Plant Sci. 2018, 9.

68. Chandrasekaran, J.; Brumin, M.; Wolf, D.; Leibman, D.; Klap, C.; Pearlsman, M.; Sherman, A.; Arazi, T.; Gal-On, A. Development of broad virus resistance in non-transgenic cucumber using CRISPR/Cas9 technology. Mol. Plant Pathol. 2016, 17, 1140–1153.
69. Sauer, N.J.; Narváez-Vásquez, J.; Mozoruk, J.; Miller, R.B.; Warburg, Z.J.; Woodward, M.J.; Mihiret, Y.A.; Lincoln, T.A.; Segami, R.E.; Sanders, S.L.; et al. Oligonucleotide-mediated genome editing provides precision and function to engineered nucleases and
Antibiotics in plants. Plant Physiol. 2016, 170, 1917–1928.

.

Copyright & License:

© Authors retain the copyright of this article. This work is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), permitting unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.